Kristen A. Johnson

Boston, Massachusetts
(617) 475-1961
Practice Areas

Class-action Litigation

Consumer Fraud




Boston College Law School, J.D.

Dartmouth College, B.A.


Kristen A. Johnson is a partner in Hagens Berman Sobol Shapiro LLP’s Boston office, where she has worked since 2007.  She combats waste, fraud, and abuse in the healthcare industry.    Ms. Johnson enjoys trying cases, writing briefs, and working closely with experts; she focuses on explaining complex cases and technical issues in simple and persuasive terms.

Ms. Johnson’s successes include a $350 million settlement on behalf of third party payers in the Neurontin marketing litigation.  Ms. Johnson was also instrumental in the recent Prograf ($98 million), Flonase ($150 million), and Wellbutrin XL ($37.5 million partial settlement) antitrust settlements. 

Ms. Johnson is court appointed alternate lead counsel in the In re New England Compounding Pharmacy Litigation Multidistrict Litigation (D. Mass., MDL 2419).  During the nascent stages of the MDL, Ms. Johnson was personally appointed liaison counsel to speak for the at least 751 victims who contracted fungal meningitis or suffered other serious health problems as a result of receiving contaminated products produced by NECC.  A proposed Chapter 11 Plan of reorganization includes estimated contributions of about $200 million which, after fees and expenses, will benefit tort victims.

Ms. Johnson was one of four attorneys who presented or cross examined witnesses for the plaintiffs during the 2014 Nexium Antitrust trial.

In 2014, the National Law Journal honored Ms. Johnson as one of the 40 lawyers under 40 in Boston.  In 2011, Public Justice nominated Ms. Johnson and the rest of her trial team for Trial Lawyer of the Year for their work securing a $142 million RICO verdict against Pfizer for fraudulently marketing the drug Neurontin. 

Ms. Johnson is actively involved in In re Nexium Antitrust Litigation (D. Mass., MDL No. 2409); In re Loestrin Antitrust Litigation (D.R.I., MDL No. 2472); and In re Celebrex Antitrust Litigation (E.D. Va., 14-cv-00361)., MDL No. 2332).

Ms. Johnson graduated cum laude from Dartmouth College and earned her J.D. at Boston College Law School. 

Ms. Johnson is admitted to practice in the Commonwealth of Massachusetts, the District of Massachusetts, and the First Circuit Court of Appeals.  She is a member of the American Association for Justice and Public Justice’s Class Action Preservation Project Committee.

Notable Cases

  • Pfizer Neurontin RICO Litigation
    $142 million jury verdict
  • In re Flonase Antitrust Litigation
    Trial January 2013
  • Zyprexa RICO Marketing Litigation and Appeal

Legal Activities

  • Public Justice – Class Action Preservation Committee
  • American Association for Justice 

Awards/ Recognition

In 2011, Public Justice nominated Ms. Johnson and the rest of the Neurontin trial team for Trial Lawyer of the Year for their work in securing a $142 million verdict against Pfizer for suppressing and manipulating the results of scientific studies that showed Neurontin did not work to treat the off-label indications Pfizer was heavily promoting.